A generic platform for the immobilisation of engineered biocatalysts

Matthew P. Thompson; Sasha R. Derrington; Rachel S. Heath; Joanne L. Porter; Juan Mangas-Sanchez; Paul N. Devine; Matthew D. Truppo; Nicholas J. Turner

doi:10.1016/j.tet.2018.12.004

A generic platform for the immobilisation of engineered biocatalysts

Matthew P. Thompson, Sasha R. Derrington, Rachel S. Heath, Joanne L. Porter, Juan Mangas-Sanchez, Paul N. Devine, Matthew D. Truppo, Nicholas J. Turner^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

210 Downloads (Pure)

Abstract

The application of biocatalysis in the pharmaceutical industry is rapidly growing as a result of increased access to enzymes that meet the demands of industrial processes. This expansion of activity has led to a corresponding increase in the demand for immobilised enzymes. EziG™ (EnginZyme AB, Sweden) is marketed as a general matrix for enzyme immobilisation on controlled porosity glass. In this work we identified criteria for a “general” enzyme immobilisation technology in the context of the requirements of the pharmaceutical industry. We subsequently evaluated EziG™ for generality in a series of case studies for the application of immobilised biocatalysts. In this study we have focussed on the challenges facing both academic and industrial applications such as enzyme stability, multistep reactions and reactions in continuous flow.

Original language	English
Pages (from-to)	327-334
Number of pages	8
Journal	Tetrahedron
Volume	75
Issue number	3
Early online date	6 Dec 2018
DOIs	https://doi.org/10.1016/j.tet.2018.12.004
Publication status	Published - 18 Jan 2019

Keywords

Biocatalysis
Controlled-pore glass
Engineered enzymes
Immobilisation

Research Beacons, Institutes and Platforms

Manchester Institute of Biotechnology

Access to Document

10.1016/j.tet.2018.12.004

Thompson et alAccepted author manuscript, 2.62 MBLicence: CC BY-NC-ND

Cite this

@article{9984b46215cc4a379372ff3eda11252f,

title = "A generic platform for the immobilisation of engineered biocatalysts",

abstract = "The application of biocatalysis in the pharmaceutical industry is rapidly growing as a result of increased access to enzymes that meet the demands of industrial processes. This expansion of activity has led to a corresponding increase in the demand for immobilised enzymes. EziG{\texttrademark} (EnginZyme AB, Sweden) is marketed as a general matrix for enzyme immobilisation on controlled porosity glass. In this work we identified criteria for a “general” enzyme immobilisation technology in the context of the requirements of the pharmaceutical industry. We subsequently evaluated EziG{\texttrademark} for generality in a series of case studies for the application of immobilised biocatalysts. In this study we have focussed on the challenges facing both academic and industrial applications such as enzyme stability, multistep reactions and reactions in continuous flow.",

keywords = "Biocatalysis, Controlled-pore glass, Engineered enzymes, Immobilisation",

author = "Thompson, {Matthew P.} and Derrington, {Sasha R.} and Heath, {Rachel S.} and Porter, {Joanne L.} and Juan Mangas-Sanchez and Devine, {Paul N.} and Truppo, {Matthew D.} and Turner, {Nicholas J.}",

year = "2019",

month = jan,

day = "18",

doi = "10.1016/j.tet.2018.12.004",

language = "English",

volume = "75",

pages = "327--334",

journal = "Tetrahedron",

issn = "0040-4020",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - A generic platform for the immobilisation of engineered biocatalysts

AU - Thompson, Matthew P.

AU - Derrington, Sasha R.

AU - Heath, Rachel S.

AU - Porter, Joanne L.

AU - Mangas-Sanchez, Juan

AU - Devine, Paul N.

AU - Truppo, Matthew D.

AU - Turner, Nicholas J.

PY - 2019/1/18

Y1 - 2019/1/18

N2 - The application of biocatalysis in the pharmaceutical industry is rapidly growing as a result of increased access to enzymes that meet the demands of industrial processes. This expansion of activity has led to a corresponding increase in the demand for immobilised enzymes. EziG™ (EnginZyme AB, Sweden) is marketed as a general matrix for enzyme immobilisation on controlled porosity glass. In this work we identified criteria for a “general” enzyme immobilisation technology in the context of the requirements of the pharmaceutical industry. We subsequently evaluated EziG™ for generality in a series of case studies for the application of immobilised biocatalysts. In this study we have focussed on the challenges facing both academic and industrial applications such as enzyme stability, multistep reactions and reactions in continuous flow.

AB - The application of biocatalysis in the pharmaceutical industry is rapidly growing as a result of increased access to enzymes that meet the demands of industrial processes. This expansion of activity has led to a corresponding increase in the demand for immobilised enzymes. EziG™ (EnginZyme AB, Sweden) is marketed as a general matrix for enzyme immobilisation on controlled porosity glass. In this work we identified criteria for a “general” enzyme immobilisation technology in the context of the requirements of the pharmaceutical industry. We subsequently evaluated EziG™ for generality in a series of case studies for the application of immobilised biocatalysts. In this study we have focussed on the challenges facing both academic and industrial applications such as enzyme stability, multistep reactions and reactions in continuous flow.

KW - Biocatalysis

KW - Controlled-pore glass

KW - Engineered enzymes

KW - Immobilisation

U2 - 10.1016/j.tet.2018.12.004

DO - 10.1016/j.tet.2018.12.004

M3 - Article

AN - SCOPUS:85058673036

SN - 0040-4020

VL - 75

SP - 327

EP - 334

JO - Tetrahedron

JF - Tetrahedron

IS - 3

ER -

A generic platform for the immobilisation of engineered biocatalysts

Abstract

Keywords

Research Beacons, Institutes and Platforms

Access to Document

Fingerprint

Cite this